和黄医药(00013.HK) 公布,将收到一笔来自合作伙伴武田(TAK.US) 的1,000万美元里程碑付款。武田于今年12月在西班牙取得FRUZAQLA®,用于治疗经治的转移性结直肠癌患者获纳入公共医疗保障范围的建议,这是在欧洲取得的首个纳入公共医疗保障范围的建议。
公告指,FRUZAQLA®于今年6月在欧盟取得欧盟委员会批准。武田拥有在中国内地、香港和澳门以外进一步开发、商业化和生产呋喹替尼的全球独家许可。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2024-12-12 16:25。) (美股为即时串流报价; OTC市场股票除外,资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.